Pre-earnings brief
Reports
Wed, Oct 28, 2026
Est. EPS
$1.16
Est. revenue
$7.6B
Implied move
±6.0%
EPS beat rate
25%
GSK plc is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $101 billion, it plays a crucial role in addressing health challenges worldwide, particularly in infectious diseases and chronic conditions.
Last quarter
In the last quarter, GSK reported an EPS of $0.45, significantly below the estimate of $0.88, leading to a stock increase of 2.79% the following day despite the miss. Investors are keen to see if this trend continues or if the company can recover.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-32.34%
Avg 1-day reaction
-0.73%
Analysts are cautiously optimistic about GSK's upcoming earnings, with expectations for modest growth in EPS and revenue. However, given the company's recent performance, there is uncertainty about meeting these targets.
Bull case
If GSK can exceed the EPS and revenue estimates, it may signal a turnaround in performance and restore investor confidence.
Bear case
Conversely, another earnings miss could further erode trust in management's ability to deliver on growth promises, leading to a negative reaction in the stock.
Key metrics to watch
EPS
$1.16Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$7.6BTotal revenue reflects the company's ability to generate sales and is critical for assessing growth.
The print will turn on these.
Q1
Will GSK achieve an EPS of at least $1.16?
This figure is critical as it sets the benchmark for market expectations and reflects the company's profitability.
Q2
Can GSK report revenue of $7.6 billion or more?
Revenue performance is essential for assessing the company's growth trajectory and overall health.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±10.3%
Why consensus could be wrong
The Street may be underestimating GSK's potential for a turnaround given its recent investments in R&D, which could yield better-than-expected results.
Supporting evidence
Options pricing suggests a larger move than historical averages, indicating potential for significant surprises.
The recent stock performance following earnings misses shows resilience, suggesting that investors may be overly cautious.
The company's focus on innovative therapies may not be fully reflected in current consensus estimates.
Key risk
If GSK's revenue exceeds $7.7 billion, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's earnings will be pivotal in determining whether GSK can recover from recent misses and regain investor confidence.
Bull confirmed if
An EPS of $1.18 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $1.15 would confirm the bear case, signaling ongoing challenges in profitability.
What the market is pricing for the move.
Implied Move
±10.8%
Historical Avg
±2.0%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±6.0% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
23.2%
Smart-money positioning from the most recent 13F filings.
Institutional
17.47%
of float
Insider
0.06%
of float
Holders
1,207
institutions
Top Holders· as of Jun 2026
FMR, LLC
64,961,641 sh · $3.1B
3.21%
-4.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns indicating an average drop of about 0.83%.
The lines on the call that would change the story.
Dodge & Cox Inc.
48,197,514 sh · $2.3B
2.38%
-17.8%
Fisher Asset Management, LLC
35,722,792 sh · $1.7B
1.77%
3.5%
Primecap Management Company
25,182,068 sh · $1.2B
1.24%
-0.1%
Wellington Management Group, LLP
11,396,249 sh · $535.9M
0.56%
-2.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.